Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Breast Neoplasms 26Prostatic Neoplasms 5Stomach Neoplasms 3Neoplasms 3Carcinoma, Renal Cell 3Carcinoma, Ovarian Epithelial 3Carcinoma, Non-Small-Cell Lung 3Sarcoma 2Rectal Neoplasms 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Neoplasm Metastasis 2Lymphoma, Mantle-Cell 2Lymphoma, Follicular 2Esophageal Neoplasms 2Colorectal Neoplasms 2Colonic Neoplasms 2Breast Neoplasms, Male 2Adenocarcinoma Of Esophagus 2Wilms Tumor 1Waldenstrom Macroglobulinemia 1Uterine Cervical Neoplasms 1Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Tongue Neoplasms 1Testicular Neoplasms 1Testicular Germ Cell Tumor 1Teratoma 1Squamous Cell Carcinoma of Head and Neck 1

Interventions

Gemcitabine 2Docetaxel 2pegfilgrastim 1pazopanib 1ixabepilone 1Thalidomide 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Epothilones 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Recurrent Uterine Corpus Sarcoma × ixabepilone × Clear all
NCT01168232 2019-08-08

Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer

National Cancer Institute (NCI)

Phase 2 Completed
42 enrolled 10 charts
GynecologicSarcoma

Recurrent Uterine Corpus Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡